Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals, Inc. - Common Stock (NQ:ANEB)

1.460 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anebulo Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MiNK Therapeutics (NASDAQ:INKT) shares rose 16.88% to $16.96 during Friday's regular session. Vocera Communications (NYSE:VCRA) shares increased by 12.13% to $... 
Via Benzinga
Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
The Risks of Cannabis Over-Consumption
Photo by Olga Ko... 
Via Benzinga
Topics Cannabis
CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication
The legalization of recreational cannabis in a number of states is associated with the increasing problem of acute cannabis intoxication (ACI). 
Via Benzinga
Topics Cannabis
Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
Photo by Elsa Olofsson 
Via Benzinga
Topics Cannabis
Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
The Unintended Consequences of Ever-Increasing Marijuana Potency
Photo by Tim Foster... 
Via Benzinga
Topics Cannabis
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
Topics Cannabis
The Treatment of Cannabis Toxicity
The increasing prevalence and potency of cannabis following the legalization of recreational marijuana sales in a number of states have also increa... 
Via Benzinga
Topics Cannabis
Cannabis Legalization is Driving an Increase in Related ER Visits
The legalization of both medical use and recreational use of cannabis in the United States has lead to an increase in both availability and potency... 
Via Benzinga
Topics Cannabis
Alcohol, Cannabis and Synergistic Risk
Although cannabis use is considered relatively benign, there is an increasing appreciation of the 
Via Benzinga
Topics Cannabis
Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year
The burden on the healthcare system from cannabis use is often underappreciated, because many see the risks of smoking marijuana as low. However, t... 
Via Benzinga
Topics Cannabis
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users
Photo by camilo jimenez on... 
Via Benzinga
Topics Cannabis
Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
The Danger of Synthetic Cannabinoids
A problem of increasing social importance is the rise in the use of synthetic cannabis alternatives, commonly called K2 or Spice or a number of oth... 
Via Benzinga
Topics Cannabis
Anebulo is Developing an Antidote to Cannabis Intoxication
The company Anebulo Pharmaceuticals (NASDAQ: ANEB) is investing in an antidote for cannabis intoxication. The social and medical issues associated with acute cannabis intoxication... 
Via Benzinga
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Ascendis Pharma (NASDAQ:ASND) st... 
Via Benzinga
Cannabis Movers & Shakers: Creo, Harvest Health & Recreation, Glass House, Flora Growth, Anebulo, Cannformatics, Republic Brands
Creo Taps Graeme Kenny To Serve As New CRO Cannabinoid ingredient company Creo has appointed Graeme Kenny as i... 
Via Benzinga
Topics Cannabis
Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
The Underappreciated Risk Of Pediatric Cannabis Overdose
There are major risks associated with the consumption of large amounts of cannabis by young children. Unlike in adults, the risks to children 
Via Benzinga
Topics Cannabis
The Dark Side of Cannabis Legalization and one Biotech Company's Solution
Photo credits: Tim Foster As of July 2021, 18 states have legalized recreational marijuana while another 18 have legalized cannabis solel... 
Via Benzinga
Topics Cannabis
Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
Topics Cannabis
Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.